Published in World J Gastroenterol on July 07, 2015
Pancreatitis as a rare manifestation of Behçet disease. JAAD Case Rep (2017) 0.75
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology (2011) 12.09
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (2008) 10.47
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet (2007) 7.81
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis (2010) 6.75
Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol (1990) 5.66
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet (2009) 5.03
Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology (2013) 4.11
Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology (2013) 3.45
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology (2000) 2.99
Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med (1995) 2.95
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol (2012) 2.88
Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology (2000) 2.78
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol (2010) 2.74
Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics (2002) 2.68
The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut (2002) 2.00
Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology (2013) 1.79
Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev (2009) 1.74
Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol (2008) 1.49
Adverse effects of azathioprine in the treatment of inflammatory bowel disease. Rev Esp Enferm Dig (2001) 1.44
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol (2011) 1.42
Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol (2007) 1.39
British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011. Br J Dermatol (2011) 1.23
Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther (2005) 1.20
Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf (2004) 1.17
Review article: explaining risks of inflammatory bowel disease therapy to patients. Aliment Pharmacol Ther (2010) 1.10
Thiopurine treatment in inflammatory bowel disease: response predictors, safety, and withdrawal in follow-up. J Crohns Colitis (2011) 1.10
Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis (2010) 1.09
Environment and the inflammatory bowel diseases. Can J Gastroenterol (2013) 1.07
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev (2010) 1.07
Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J Gastroenterol (2006) 1.07
Drug-related hepatotoxicity. N Engl J Med (2006) 1.00
Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther (2006) 0.99
Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther (2008) 0.99
5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis (2006) 0.99
Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther (2008) 0.97
The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. Clin Gastroenterol Hepatol (2010) 0.95
Ethnic variation of thiopurine S-methyltransferase activity: a large, prospective population study. Pharmacogenomics (2008) 0.89
Interethnic difference in thiopurine methyltransferase activity. Clin Pharmacol Ther (1992) 0.89
Safety of thiopurines in the treatment of inflammatory bowel disease. Scand J Gastroenterol Suppl (2003) 0.87
Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease. Gastroenterol Hepatol (2011) 0.87
Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. Dig Dis Sci (2007) 0.86
The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol (2012) 0.84
The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice. Dig Liver Dis (2008) 0.83
Phenotypic features of Crohn's disease associated with failure of medical treatment. Clin Gastroenterol Hepatol (2013) 0.82
Assessment of thiopurine methyltransferase activity in patients prescribed azathioprine or other thiopurine-based drugs. Evid Rep Technol Assess (Full Rep) (2010) 0.81
Thiopurine S-methyltransferase (TPMT) pharmacogenetics: three new mutations and haplotype analysis in the Estonian population. Clin Chem Lab Med (2008) 0.80
Gender difference in red blood cell thiopurine methyltransferase activity. Scand J Clin Lab Invest (1993) 0.79
MTHFR and TYMS genotypes influence TPMT activity and its differential modulation in males and females. Clin Biochem (2009) 0.78
Thiopurines in Crohn's disease, is there something new? Expert Opin Drug Metab Toxicol (2010) 0.78
Current status of thiopurine analogues in the treatment in Crohn's disease. World J Gastroenterol (2011) 0.78
Azathioprine or mercaptopurine-induced acute pancreatitis is not a disease-specific phenomenon. Aliment Pharmacol Ther (2010) 0.77
Pre-analytic and analytic sources of variations in thiopurine methyltransferase activity measurement in patients prescribed thiopurine-based drugs: A systematic review. Clin Biochem (2011) 0.76